drugset / Trial / NCT04465916
Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)
Phase 2
Terminated
26 enrolled
Enyo Pharma
Eurofins · collabNovotech (Australia) Pty Limited · collabParexel · collabSynteract, Inc. · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a prospective, multi-centre, randomized, double-blind, placebo-controlled, Phase 2a experimental study of oral FXR modulator EYP001a/placebo combined with NAs in virologically suppressed CHB patients to improve functional cure rates.
Timeline
- Start
- 2020-05-12
- Primary completion
- 2021-06-17
- Completion
- 2021-11-25
Outcome
Outcome not reported
Stopped: “DSMC reviewed results of 26 subjects. New randomizations were stopped. Already randomized subjects were followed up to W40.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EYP001a | Unknown | — | Oral |
| Background | Entecavir | Small molecule | — | Oral |
| Background | Tenofovir disoproxil fumarate | Small molecule | — | Oral |